Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.31 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910837 | 0.86 | HTT (0.36) | HTTL3MBTL1USP2HSP90AB1 | |
| SCHEMBL8259796 | 0.71 | LMNA (0.41) | L3MBTL1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5271685 | 0.71 | NOS2 (0.38) | KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL15427846 | 0.67 | HTT (0.62) | HTTL3MBTL1SOAT1ALDH1A1HPGD | |
| SCHEMBL4909159 | 0.67 | PIK3C3 (0.35) | L3MBTL1KDM4EALDH1A1HPGDHSP90AB1 | |
| SCHEMBL20772445 | 0.66 | CNR2 (0.47) | HTTL3MBTL1ALDH1A1SMN1; SMN2CNR2 | |
| SCHEMBL8328435 | 0.66 | NOS2 (0.46) | HTTL3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL5681020 | 0.65 | HTT (0.38) | HTTL3MBTL1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14327935 | 0.65 | NPC1 (0.41) | HTTL3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL4902037 | 0.65 | PDE11A (0.40) | L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-06-05 | — | — | US | disclosed |
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-06-05 | — | — | US | disclosed |
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-06-05 | — | — | US | disclosed |
| EP-1838152-A2 | IMIDAZOLYLMETHYL AND PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006078891-A2 | IMIDAZOLYLMETHYL AND PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078891-A2 | IMIDAZOLYLMETHYL AND PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | GABRR3, GABRA3, GABRR1 | HTT 3260/4885L3MBTL1 1503/4885SOAT1 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.